The company has received EIR from the United States Food and Drug Administration (USFDA) after inspection of its Goa facility from April 3-7, 2017, Marksans Pharma said in a BSE filing.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Shares of Marksans Pharma were today trading 2.30 per cent higher at Rs 48.85 per scrip in the afternoon trade on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content